Canada: Supreme Court Of Canada Rejects The Promise Of The Patent Doctrine

The Supreme Court of Canada released on June 30, 2017 its long-awaited decision1 (available here) addressing the issue of the "promise of the patent." The Promise Doctrine required patentees to establish arguable statements of utility in the patent disclosure or risk losing their patents. In its reasons, the Court confirmed what many patentees have been arguing for more than a decade – that the "excessively onerous" Promise Doctrine is unsound and not the correct method for determining whether an invention has sufficient utility under section 2 of the Patent Act.

In discarding this recent judicial construct, the Court focused on the requirements of the Patent Act and re-emphasized the centrality of the established patent doctrine of purposive claims construction. The Court provided guidance on how to correctly assess a claimed invention's utility and emphasized the low threshold for utility, namely a scintilla of utility. The Supreme Court thus refocused the utility requirement on its traditional purpose of preventing "patenting of fanciful, speculative or inoperable inventions" rather than invalidating patents for inventive, novel and otherwise useful inventions.

Applying this framework, the Court allowed AstraZeneca's appeal and found that its patent was valid, overturning both underlying Courts.


AstraZeneca sold esomeprazole (a proton pump inhibitor) in Canada as the commercially successful product Nexium®. AstraZeneca owned Canadian Patent 2,139,653, which claims a novel salt of this compound.

Apotex sought to market a generic copy of esomeprazole and thus sought to impeach the 653 Patent. Apotex alleged the patent was invalid for, among other things, inutility. The Trial Judge's utility analysis turned on its application of the Promise Doctrine to the following stray statement in the patent disclosure:

It is desirable to obtain compounds with improved pharmacokinetic and metabolic properties which will give an improved therapeutic profile such as a lower degree of interindividual variation. The present invention provides such compounds, which are novel salts of single enantiomers of omeprazole. (emphasis added by the Federal Court)

The Trial Judge concluded that this statement constituted a "promise of the patent" which is "fundamental to the utility analysis" as the "yardstick against which utility is measured".  While there was no dispute that AstraZeneca had demonstrated that the claimed compound was a useful PPI, the Trial Judge nonetheless found the patent invalid for lack of utility as AstraZeneca had not demonstrated or soundly predicted the promise of an improved profile as of the filing date. The Federal Court of Appeal adopted the Trial Judge's analysis and affirmed both the status and application of the Promise Doctrine.

The Promise Doctrine is unsound and inconsistent with the Patent Act

The Supreme Court began its analysis by pointing out an immediately apparent flaw with the Promise Doctrine. That is, issues of validity generally focus on the claims alone, turning only to disclosure if there is ambiguity in the claims. The Promise Doctrine, however, improperly directs courts to consider the disclosure to identify potential promises irrespective of any such ambiguity.

The Court then held that the Promise Doctrine runs counter to the scheme of the Patent Act by conflating two of its requirements. The Court distinguished the section 2 requirement that an invention be "useful" and the section 27(3) requirement to disclose an invention's "operation or use", noting that the Supreme Court previously sought to clarify this very confusion in an earlier seminal patent decision.2 The Court rejected the notion that the reference to a "promise" in an oft-cited passage in that decision referred to or embodied the Promise Doctrine. The Court thus found that the Promise Doctrine inappropriately imports the section 27(3) requirement into section 2 by requiring that any use disclosed in the patent be demonstrated or soundly predicted at the time of filing.

The Court also found the Promise Doctrine to be inconsistent with the Patent Act because it requires that multiple uses be established. However, section 2 of the Act requires only that the invention be "useful". Any single use that is demonstrated or soundly predicted by the filing date is sufficient. The Promise Doctrine, given that it risks depriving a useful invention of patent protection if even a single "promised" use is not established, was thus found to be punitive and have no basis in the Patent Act. The Court also added that its operation, which can invalidate a patent based on discrete unintentional overstatements of use, would discourage patentees from fully disclosing their inventions, contrary to the purpose of section 27(3).

The Correct Approach to Assessing Utility

The Court held a scintilla of utility is all that is needed (ie. the invention must not be devoid of utility) and that utility must be established by either demonstration or sound prediction as of the filing date. The utility in question will vary based on the subject-matter of the invention as identified by claims construction, and a single use related to the nature of that subject-matter is sufficient.

The Supreme Court thus provided a two-step framework for assessing a claimed invention's utility:

  1. Identify the subject-matter of the invention as claimed.
  2. Is that subject-matter useful, i.e. is it capable of a practical purpose? No degree or quantum of usefulness is required – a scintilla of utility of utility related to the nature of the subject-matter is sufficient.

The Court also clarified that a patentee is not required to disclose the utility of the invention to fulfill the requirements of s. 2 of the Patent Act.


As regards the Promise Doctrine, the Supreme Court's momentous decision thus brings Canadian patent law back in line with the rest of the world. It will no doubt be a welcome development for innovators, providing more certainty for patents which had increasingly been challenged on the basis of subjective patent interpretations and often malleable and evolving requirements.


1 AstraZeneca Canada Inc. v. Apotex Inc., 2017 SCC 36

2 Consolboard Inc. v. MacMillan Bloedel (Sask.) Ltd., [1981] 1 S.C.R. 504.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
29 Nov 2017, Seminar, London, UK

Join us at 4 More London for this breakfast seminar on Wednesday, 29 November 2017 to gain a greater understanding on this debate. Coffee and breakfast will be from 08:30 with the discussion commencing at 09:00. We will finish and have you on your way by 10:00.

7 Dec 2017, Seminar, London, UK

Would you like the opportunity to hear more about the potential disruptive effect that blockchain is going to have in the energy sector? If so, please join us on 7 December where Jo-Jo Hubbard, a leading light in this area, will explain all.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.